PREVALENCE OF ANEMIA IN PATIENTS WITH METABOLIC SYNDROME

ACADEMIC RESEARCH IN MODERN SCIENCE

International scientific-online conference

28

PREVALENCE OF ANEMIA IN PATIENTS WITH METABOLIC

SYNDROME

Saydaliyev Rustam Saydaliyevich

Tashkent medical academy

Umrzakova M.U.

Republican research center of emergency medicine, Tashkent

https://doi.org/10.5281/zenodo.14179031

Background

: Metabolic syndrome is a condition linking insulin resistance,

dyslipidemia, hyperglycemia, and hypertension that increases the risk of
developing diabetes, cardiovascular disease, and subsequent cardiovascular
morbidity and mortality. Anemia is more common and more severe in patients
with metabolic syndrome compared to patients without metabolic syndrome.
Aim: This study was undertaken to determine the prevalence of anemia and the
metabolic syndrome with special interest in the coexistence of these two
problems as well as the possible links.

Material and methods

: In a cross-sectional household survey, 97 men

and 112 women aged 20 years and above were interviewed; anthropometric
measurements and blood samples were taken. Metabolic syndrome was defined
by the International Diabetes Federation. Anaemia was defined as hemoglobin
level below 13 g/dL for men and 12 g/dL for women.

Results:

The age- adjusted prevalence of metabolic syndrome was 12,4%

and of anemia 23,9 %. About 4 percent of the participants had both anaemia and
metabolic syndrome. Women had a higher prevalence of both the metabolic
syndrome and anemia than men ( 13,4 vs 7,2 %, 29,4 % vs 15,2%). Anaemia
coexisted significantly with all the individual components of the metabolic
syndrome. Only 5,7 % of the sample had anaemia without any individual
component of metabolic syndrome. In women, the prevalence of combined
anaemia and metabolic syndrome peaked in the age group 48-58 years (9,8%).
Women in the highest quartile of serum ferritin had a higher risk of only the
metabolic syndrome and coexistence of anaemia and metabolic syndrome.

Conclusion:

The high prevalence of the metabolic syndrome and anaemia

in the area show the urgent need to develop comprehensive strategies aimed at
prevention and treatment. In women this coexistence may be related to
inflammation but further investigations is needed. Correction of anemia may
have a significant role in prevention of complications related with metabolic
syndrome.

ACADEMIC RESEARCH IN MODERN SCIENCE

International scientific-online conference

29

Использованная литература:

1. Блиндарь В.Н., Зубрихина Г.Н., Матвеева И.И. с соавт. Ферритин,
растворимые рецепторы трансферрина, эрит ропоэтин у онкологических
больных с анемическим синдромом // Материалы конгресса. XI
Российский онкологи ческий конгресс. – 2007. – С.233.
2. Вокалюк Р.М., Дворецкий Л.И., Заспа Е.А. Cтратегия и тактика ведения
больных железодефицитной анемией // Русский медицинский журнал. –
2008. – т.16. – №7. – С.443432.
3. Войнов В.А. Эфферентная терапия // 2006. – т.4. – С.304.
4. Дворецкий Л.И. Алгоритмы диагностики и лечения анемий // Русский
медицинский журнал. – 2003. – т.11. – №8. – С.427433.
5. Дементьева И.И. Клинические аспекты состояния и регуляции
кислотноосновного гомеостаза // 2003. – №2. – С.241313.
6. Henke M., Laszig R., Rube C. et al. Erythropoietin to treat head and neck cancer
patients with anaemia undergoing radiotherapy: randomised, doubleblind,
placebocontrolled trial // Lancet. – 2003. – Vol.362. – №9392. – P.1233 1260.
7. Hoffman P. C. Immune hemolytic anemia—selected topics //
Hematology.Am.Soc.Hematol.Educ.Program. – 2006. – P.1318.
8. Hoorn E.J., Halperin M.L., Zietse R. Diagnostic approach to a patient with
hyponatraemia: traditional versus physiology based options // QJM. – 2003. –
Vol.98. – №7. – P.329340.
9. Mange, Kevin, Matsuura, Dean, Cizman, Borut et al. Language Guiding
Therapy: The Case of Dehydration versus Volume Depletion // Ann.Intern.Med.
– 1997. – Vol.127. – №9. – P.848833.
10. Onitilo A.A., Kio E., Doi S.A. Tumorrelated hyponatremia // Clin. Med.Res. –
2007. – Vol.3. – №4. – P.228237.
11. Scrijvers D., Roila F. On behalf of the ESMO Guidelines Working
GroupErythropoiesisstimulating

agents

in

cancer

patients:

ESMO

Recommendations for use // Ann.Oncol. – 2009. – Vol.20, suppl. 4. –
P.iv139iv161. \
12. Tonelli M., Hemmelgarn B., Reiman T. et al. Benefits and harms of
erythropoiesisstimulating agents for anemia related to cancer: a metaanalysis //
CMAJ. – 2009. – Vol.180. – №11. – P.E62E71.